Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Chaturbhuj Agrawal"'
Autor:
Dinesh Chandra Doval, Sneha Bothra, Pankaj Goyal, Chaturbhuj Agrawal, Parveen Jain, Rupal Tripathi, Anurag Sharma, Sunil Pasricha, Kumardeep Dutta Choudhary
Publikováno v:
Asian Pacific Journal of Cancer Care, Vol 6, Iss 4, Pp 449-456 (2021)
Background: Data regarding pathologic response of Trastuzumab based chemotherapy in locally advanced HER2 positive breast cancer in neoadjuvant setting is scarce. Methods: A retrospective analysis was conducted from January 2014 to January 2019 at a
Externí odkaz:
https://doaj.org/article/ca073e01f158489290114d1862e42d0f
Autor:
Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefit
Externí odkaz:
https://doaj.org/article/0a2eee6afaf34fa489c4e65d644828a3
Autor:
Dinesh Chandra Doval, Rupal Tripathi, Sunil Pasricha, Pankaj Goyal, Chaturbhuj Agrawal, Anurag Mehta
Publikováno v:
Human Pathology: Case Reports, Vol 25, Iss , Pp 200531- (2021)
Mucinous carcinoma of breast is a rare variant of invasive breast carcinoma and usually affects older females and is associated with good prognosis. Human epidermal growth factor receptor 2 (HER2) positivity in these tumors is rare. We describe here
Externí odkaz:
https://doaj.org/article/b4ee3b94acad44fc829444a0eb671868
Autor:
Chaturbhuj Agrawal
Publikováno v:
Medical Journal of Dr. D.Y. Patil Vidyapeeth, Vol 11, Iss 1, Pp 85-87 (2018)
Externí odkaz:
https://doaj.org/article/dee4e495cf024b7094212700e7c169c1
Publikováno v:
Archives of Medicine and Health Sciences, Vol 5, Iss 2, Pp 245-247 (2017)
Aromatase inhibitors are approved hormonal agents for the treatment of breast cancer since the past few decades. These agents are usually well tolerated except some common side effects seen in day-to-day practice such as arthralgia and mood changes.
Externí odkaz:
https://doaj.org/article/92f4174202de4b56b3b104dfda9db5cc
Publikováno v:
South Asian Journal of Cancer, Vol 6, Iss 2, Pp 86-87 (2017)
Externí odkaz:
https://doaj.org/article/dc524ce215444a7b87e2ac9ca2e1c9e3
Publikováno v:
Archives of Medicine and Health Sciences, Vol 5, Iss 1, Pp 137-138 (2017)
Externí odkaz:
https://doaj.org/article/557456a63042415cbb40f300270b3a27
Autor:
Kumardeep Dutta Choudhary, Sunil Pasricha, Anurag Sharma, Rupal Tripathi, Parveen Jain, Chaturbhuj Agrawal, Pankaj Goyal, Sneha Bothra, Dinesh Chandra Doval
Publikováno v:
Asian Pacific Journal of Cancer Care. 6:449-456
Background: Data regarding pathologic response of Trastuzumab based chemotherapy in locally advanced HER2 positive breast cancer in neoadjuvant setting is scarce. Methods: A retrospective analysis was conducted from January 2014 to January 2019 at a
Autor:
Pankaj Goyal, Praveen Jain, Chaturbhuj Agrawal, Sneha Bothra Jain, Vineet Talwar, Ullas Batra, Sumit Goyal, Udip Maheshwari, Krushna Chaudhari, Varun Goel, Amrith BP, Dinesh Chandra Doval
Publikováno v:
Indian Journal of Medical and Paediatric Oncology.
The molecular pathogenesis of breast cancer (BC), the second most common cancer, varies significantly between sexes, with minimal data in the transgender population. The overall prevalence of BC in transgenders is estimated to be 0.02%. Besides exper
Autor:
Sunil Pasricha, Gurudutt Gupta, Rupal Tripathi, Ullas Batra, Anila Sharma, Venkata Pradeep Babu Koyyala, Meenakshi Kamboj, Dinesh Chandra Doval, Garima Durga, Vidya Madhusoodhanan Menon, Chaturbhuj Agrawal, Ankush Jajodia, Anurag Mehta
Publikováno v:
The Breast Journal. 26:2213-2216
Human epidermal growth factor receptor 2 (HER-2) is an established prognostic and predictive biomarker for breast cancer. To ensure accuracy and uniformity for HER-2 testing, ASCO/CAP published guidelines in 2007 which were updated in 2013 and recent